Tag Archives: Reports

Recent Reports State That 19 Million Americans Abuse Prescription Drugs; FDA and Novus Medical Detox Agree That Education is Needed


New Port Richey, FL (PRWEB) August 11, 2014

Reports from the Centers for Disease Control and Prevention (CDC) state that 46 Americans die every day from prescription drug overdose, which adds up to about 17,000 deaths annually. The reports also state that poisonings by drug overdose have tripled over the past 30 years. (1) Novus Medical Detox, one of the only Florida-based detox centers serving high-dosage drug abuse patients, states that the reason behind the high number of fatalities lies in inadequate drug education.

The Food and Drug Administration (FDA) carries this same belief, and has responded by implementing a new drug education program. The program seeks to educate doctors who prescribe these highly-addictive painkillers, as well as the patients who are taking them. The program’s mission is “to teach doctors about proper opiate prescribing for pain patients to minimize the risks of diversion and addiction.” (4)

The United Nation’s World Drug Report 2014 stated that in 2012, 6.1% (19 million) of Americans abused prescription opioids, including morphine, codeine, OxyContin and Vicodin. This figure categorizes the United States as a country that abuses prescription drugs more than any other country in the world. (2) In an effort to lower the number of people harmed by these drugs, Novus warns Americans to exercise caution when receiving a new prescription from a physician, and to ask questions related to its side effects.

“Intentionally or not, Americans may be underestimating the highly addictive nature of drugs such as opioids,” stated Novus Executive Director Kent Runyon. “It may start as nothing more than filling a prescription for legitimate pain, but overdose may result when a patient seeks to elicit a stronger high from these drugs.”

Novus recommends that the following steps be taken when being prescribed a new medication (3):

●    Be sure that the prescription comes from a trusted physician;

●    Only use the medication as prescribed;

●    Ask the physician about the medicine and its effects;

●    Conduct your own research about the drug’s effects; and

●    Be prepared—ask your doctor what to do if one becomes addicted.

All of these tips are important to heed before a patient starts to take a medication, because addiction may begin with the patient being unaware of a medication’s initial effects. This patient may begin to take pills more liberally than prescribed, and the dangers of addiction do not lie far behind.

Runyon maintains that comprehensive drug education, starting in grade school and continuing throughout adult life to physician visits, can help to significantly reduce the number of Americans addicted to such drugs.

While new preventative measures are being taken, Novus recommends looking out for the following symptoms or behaviors (but not limited to), if someone suspects that a loved one is abusing pain reliever prescription drugs (5):

●    Nausea, drowsiness;

●    Mood swings and anxiety;

●    Slowed reactions, movement and breathing;

●    Jittery or secretive; and/or

●    Neglect of work/school responsibilities.

Runyon advises those who are dependent upon any abusive substance(s) to seek out safe, medically-supervised detox programs, and to use those with integrated medicine that allows the detox process to be as comfortable as possible.

For more information on Novus Medical Detox’s addiction and detox programs, visit http://www.NovusDetox.com.

About Novus Medical Detox Center:

Novus Medical Detox Center offers safe, effective alcohol and drug treatment programs in a home-like residential setting. Located on 3.25 tree-lined acres in New Port Richey, Fla., Novus is licensed by the Florida Department of Children and Families as an inpatient medical detox facility. Novus is known for minimizing the discomfort of withdrawal from prescription medication, drugs or alcohol by creating a customized detox program for each patient, incorporating medication, natural supplements and fluid replenishment—putting the dignity and humanity back into drug detoxification. Patients have 24/7 medical supervision, including round-the-clock nursing care and access to a withdrawal specialist, and enjoy comfortable private or shared rooms with a telephone, cable television, and high-speed Internet access. For more information, visit http://www.novusdetox.com.

1.Hutchins, Sarah. “Drug Overdose: Prescription Painkillers Poison 46 Americans Every Day.” Liberty Voice, 20 July 2014. Web. 22 July 2014. guardianlv.com/2014/07/drug-overdose-prescription-painkillers-poison-46-americans-every-day/.

2.Blake, Matthew. “Extent of US Dependency on Prescription Drugs Revealed: UN Report Shows 6% of American Adults Hooked on Pills.” Mail Online. Associated Newspapers, 07 July 2014. Web. 21 July 2014. dailymail.co.uk/news/article-2683318/Extent-US-dependency-prescription-drugs-revealed-UN-report-shows-6-American-adults-hooked-pills.html.

3.Winkel, Bethany. “Avoiding Prescription Drug Abuse—Treatment Solutions.” Treatment Solutions. N.p., 11 Feb. 2010. Web. 23 July 2014. treatmentsolutions.com/avoiding-prescription-drug-abuse/.

4.Sack, David. “FDA Prescription Drug Abuse Plan Hits—and Misses—the Mark—Addiction Recovery.” Addiction Recovery with David Sack, M.D. Psych Central.com, 7 July 2014. Web. 22 July 2014. blogs.psychcentral.com/addiction-recovery/2014/07/fda-prescription-drug-abuse-plan-hits-and-misses-the-mark/.

5.“Signs and Symptoms of Prescription Pain Reliever Abuse.” Narconon International, n.d. Web. 22 July 2014. narconon.org/drug-abuse/signs-symptoms-pain-relievers.html.







Risperdal Lawsuit Claims Contending Males Taking The Antipsychotic Drug Causes Gynecomastia Move Forward With October Meeting Reports Wright & Schulte LLC


Columbus, OH (PRWEB) October 11, 2014

As Risperdal lawsuit claims continue in the Philadelphia Court of Common Pleas, another monthly meeting has been scheduled for parties to discuss the litigation surrounding antipsychotic drugs and the development of male breasts or gynecomastia. According to court records there are nearly 80 Risperdal lawsuit claims pending in the Philadelphia Court of Common Pleas mass tort program. The court’s calendar shows attorneys for the plaintiffs and defendants are scheduled to meet on October 15, at the Complex Litigation Center in Philadelphia’s City Hall. The Risperdal side-effects complaints were filed on behalf of males who allege that they experienced gynecomastia, which is excessive male breast growth similar to that of a woman after using the antipsychotic drug. The Risperdal side-effect lawsuits purport that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., which manufactures and markets the drug, failed to warn consumers and health care providers about the serious side-effects of taking Risperdal. (In Re: Risperdal Litigation, Case Number 100300296)

Risperdal gynecomastia is a devastating condition that can have far reaching effects on a boy’s social development and quality of life. The attorneys at Wright & Schulte LLC are committed to ensuring that the victims of Risperdal gynecomastia obtain the justice they deserve. To learn more, please contact Wright & Schulte LLC for a free Risperdal lawsuit consultation to ensure you are treated fairly and receive all of the compensation the law allows. Call 1-800-399-0795 or visit http://www.yourlegalhelp.com for more information.

In June, plaintiffs’ attorneys asked Philadelphia Court of Common Pleas Judge Arnold New, who is presiding over the Risperdal litigation, to reconsider his decision of preventing plaintiffs from asking for punitive damages against Janssen Pharmaceuticals, Inc. Judge New issued an order on July 18 reaffirming his earlier decision to deny punitive damages to plaintiffs but they can still ask for compensatory damages. The issue of punitive damages arose as a result of Janssen asking Judge New to allow the New Jersey Product Liability Act to apply in the Risperdal litigation because the company is headquartered in New Jersey. The New Jersey Product Liability Act does not allow punitive damages to be awarded against manufacturers of prescription drugs or medical devices if they have received pre-market approval by the U.S. Food & Drug Administration (FDA). Plaintiffs’ attorneys contend that the defendants marketed Risperdal for uses that were not approved by the FDA and therefore, punitive damages should be allowed. Judge New initially granted Janssen’s motion in an order issued May 2, 2014. (In Re: Risperdal Litigation, Case Number 100300296)

Janssen Pharmaceuticals, Inc., was the subject of a criminal investigation by the U.S. Department of Justice (DOJ) for marketing Risperdal for uses that were not approved by the FDA. According to the DOJ, Janssen did not have FDA approval when the company marketed the antipsychotic medication for use in children and adolescents with behavior challenges and the company did not disclose the health risks associated with use of the drug. In November 2013, the DOJ announced that Janssen was charged with a criminal count of misbranding Risperdal and Janssen pleaded guilty to the charge. The company also agreed to pay a $ 400 million criminal fine. The DOJ said Risperdal was not approved for use in children for any purpose until late 2006. Janssen was also under criminal investigation for marketing Risperdal for unapproved use in elderly dementia patients. The DOJ charged Janssen in this case with introducing a misbranded drug into interstate commerce. The company also paid $ 1.25 billion to settle a separate civil case regarding Risperdal. [justice.gov/opa/pr/2013/November/13-ag-1170.html, November 4, 2013] [fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373499.htm, November 4, 2013]

Risperdal is approved by the FDA as an atypical antipsychotic drug to treat schizophrenia, bipolar disorder, and irritability in autistic children and adolescents. An investigation by the Los Angeles Daily News showed children in California’s foster care system have been prescribed psychiatric drugs, including Risperdal, Prozac, and Haldol, to control their behavior, although the medications have not been approved by the FDA use by children. The Los Angeles Daily News said it looked at 10 years of data that begins in 2004. The newspaper’s investigation found that nearly 1 out of every 4 adolescents in California’s foster care system is receiving psychiatric drugs, which is three times the rate for all adolescents nationwide. The newspaper reported that of the thousands of foster children prescribed psychotropic drugs in the last 10 years, nearly 60 percent were prescribed an antipsychotic, which are the highest risk psychotropic drugs. The newspaper further reported that the percentage of foster children who were prescribed two or more psychotropic medications increased from 10.1 percent in 2004 to 12.2 percent in 2013.

[dailynews.com/health/20140823/children-in-californias-foster-care-system-are-prescribed-risky-medications, August 23, 2014]

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:

Wright & Schulte LLC

812 East National Road

Vandalia, Ohio 45377

1-800-399-0795

http://www.yourlegalhelp.com

Like us on Facebook

Follow us on Twitter

Join us on Google+







Risperdal Lawsuit Claims Contending Males Taking The Antipsychotic Drug Causes Gynecomastia Move Forward With October Meeting Reports Wright & Schulte LLC


Columbus, OH (PRWEB) October 11, 2014

As Risperdal lawsuit claims continue in the Philadelphia Court of Common Pleas, another monthly meeting has been scheduled for parties to discuss the litigation surrounding antipsychotic drugs and the development of male breasts or gynecomastia. According to court records there are nearly 80 Risperdal lawsuit claims pending in the Philadelphia Court of Common Pleas mass tort program. The court’s calendar shows attorneys for the plaintiffs and defendants are scheduled to meet on October 15, at the Complex Litigation Center in Philadelphia’s City Hall. The Risperdal side-effects complaints were filed on behalf of males who allege that they experienced gynecomastia, which is excessive male breast growth similar to that of a woman after using the antipsychotic drug. The Risperdal side-effect lawsuits purport that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., which manufactures and markets the drug, failed to warn consumers and health care providers about the serious side-effects of taking Risperdal. (In Re: Risperdal Litigation, Case Number 100300296)

Risperdal gynecomastia is a devastating condition that can have far reaching effects on a boy’s social development and quality of life. The attorneys at Wright & Schulte LLC are committed to ensuring that the victims of Risperdal gynecomastia obtain the justice they deserve. To learn more, please contact Wright & Schulte LLC for a free Risperdal lawsuit consultation to ensure you are treated fairly and receive all of the compensation the law allows. Call 1-800-399-0795 or visit http://www.yourlegalhelp.com for more information.

In June, plaintiffs’ attorneys asked Philadelphia Court of Common Pleas Judge Arnold New, who is presiding over the Risperdal litigation, to reconsider his decision of preventing plaintiffs from asking for punitive damages against Janssen Pharmaceuticals, Inc. Judge New issued an order on July 18 reaffirming his earlier decision to deny punitive damages to plaintiffs but they can still ask for compensatory damages. The issue of punitive damages arose as a result of Janssen asking Judge New to allow the New Jersey Product Liability Act to apply in the Risperdal litigation because the company is headquartered in New Jersey. The New Jersey Product Liability Act does not allow punitive damages to be awarded against manufacturers of prescription drugs or medical devices if they have received pre-market approval by the U.S. Food & Drug Administration (FDA). Plaintiffs’ attorneys contend that the defendants marketed Risperdal for uses that were not approved by the FDA and therefore, punitive damages should be allowed. Judge New initially granted Janssen’s motion in an order issued May 2, 2014. (In Re: Risperdal Litigation, Case Number 100300296)

Janssen Pharmaceuticals, Inc., was the subject of a criminal investigation by the U.S. Department of Justice (DOJ) for marketing Risperdal for uses that were not approved by the FDA. According to the DOJ, Janssen did not have FDA approval when the company marketed the antipsychotic medication for use in children and adolescents with behavior challenges and the company did not disclose the health risks associated with use of the drug. In November 2013, the DOJ announced that Janssen was charged with a criminal count of misbranding Risperdal and Janssen pleaded guilty to the charge. The company also agreed to pay a $ 400 million criminal fine. The DOJ said Risperdal was not approved for use in children for any purpose until late 2006. Janssen was also under criminal investigation for marketing Risperdal for unapproved use in elderly dementia patients. The DOJ charged Janssen in this case with introducing a misbranded drug into interstate commerce. The company also paid $ 1.25 billion to settle a separate civil case regarding Risperdal. [justice.gov/opa/pr/2013/November/13-ag-1170.html, November 4, 2013] [fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373499.htm, November 4, 2013]

Risperdal is approved by the FDA as an atypical antipsychotic drug to treat schizophrenia, bipolar disorder, and irritability in autistic children and adolescents. An investigation by the Los Angeles Daily News showed children in California’s foster care system have been prescribed psychiatric drugs, including Risperdal, Prozac, and Haldol, to control their behavior, although the medications have not been approved by the FDA use by children. The Los Angeles Daily News said it looked at 10 years of data that begins in 2004. The newspaper’s investigation found that nearly 1 out of every 4 adolescents in California’s foster care system is receiving psychiatric drugs, which is three times the rate for all adolescents nationwide. The newspaper reported that of the thousands of foster children prescribed psychotropic drugs in the last 10 years, nearly 60 percent were prescribed an antipsychotic, which are the highest risk psychotropic drugs. The newspaper further reported that the percentage of foster children who were prescribed two or more psychotropic medications increased from 10.1 percent in 2004 to 12.2 percent in 2013.

[dailynews.com/health/20140823/children-in-californias-foster-care-system-are-prescribed-risky-medications, August 23, 2014]

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:

Wright & Schulte LLC

812 East National Road

Vandalia, Ohio 45377

1-800-399-0795

http://www.yourlegalhelp.com

Like us on Facebook

Follow us on Twitter

Join us on Google+







Risperdal Lawsuit Claims Contending Males Taking The Antipsychotic Drug Causes Gynecomastia Move Forward With October Meeting Reports Wright & Schulte LLC


Columbus, OH (PRWEB) October 11, 2014

As Risperdal lawsuit claims continue in the Philadelphia Court of Common Pleas, another monthly meeting has been scheduled for parties to discuss the litigation surrounding antipsychotic drugs and the development of male breasts or gynecomastia. According to court records there are nearly 80 Risperdal lawsuit claims pending in the Philadelphia Court of Common Pleas mass tort program. The court’s calendar shows attorneys for the plaintiffs and defendants are scheduled to meet on October 15, at the Complex Litigation Center in Philadelphia’s City Hall. The Risperdal side-effects complaints were filed on behalf of males who allege that they experienced gynecomastia, which is excessive male breast growth similar to that of a woman after using the antipsychotic drug. The Risperdal side-effect lawsuits purport that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., which manufactures and markets the drug, failed to warn consumers and health care providers about the serious side-effects of taking Risperdal. (In Re: Risperdal Litigation, Case Number 100300296)

Risperdal gynecomastia is a devastating condition that can have far reaching effects on a boy’s social development and quality of life. The attorneys at Wright & Schulte LLC are committed to ensuring that the victims of Risperdal gynecomastia obtain the justice they deserve. To learn more, please contact Wright & Schulte LLC for a free Risperdal lawsuit consultation to ensure you are treated fairly and receive all of the compensation the law allows. Call 1-800-399-0795 or visit http://www.yourlegalhelp.com for more information.

In June, plaintiffs’ attorneys asked Philadelphia Court of Common Pleas Judge Arnold New, who is presiding over the Risperdal litigation, to reconsider his decision of preventing plaintiffs from asking for punitive damages against Janssen Pharmaceuticals, Inc. Judge New issued an order on July 18 reaffirming his earlier decision to deny punitive damages to plaintiffs but they can still ask for compensatory damages. The issue of punitive damages arose as a result of Janssen asking Judge New to allow the New Jersey Product Liability Act to apply in the Risperdal litigation because the company is headquartered in New Jersey. The New Jersey Product Liability Act does not allow punitive damages to be awarded against manufacturers of prescription drugs or medical devices if they have received pre-market approval by the U.S. Food & Drug Administration (FDA). Plaintiffs’ attorneys contend that the defendants marketed Risperdal for uses that were not approved by the FDA and therefore, punitive damages should be allowed. Judge New initially granted Janssen’s motion in an order issued May 2, 2014. (In Re: Risperdal Litigation, Case Number 100300296)

Janssen Pharmaceuticals, Inc., was the subject of a criminal investigation by the U.S. Department of Justice (DOJ) for marketing Risperdal for uses that were not approved by the FDA. According to the DOJ, Janssen did not have FDA approval when the company marketed the antipsychotic medication for use in children and adolescents with behavior challenges and the company did not disclose the health risks associated with use of the drug. In November 2013, the DOJ announced that Janssen was charged with a criminal count of misbranding Risperdal and Janssen pleaded guilty to the charge. The company also agreed to pay a $ 400 million criminal fine. The DOJ said Risperdal was not approved for use in children for any purpose until late 2006. Janssen was also under criminal investigation for marketing Risperdal for unapproved use in elderly dementia patients. The DOJ charged Janssen in this case with introducing a misbranded drug into interstate commerce. The company also paid $ 1.25 billion to settle a separate civil case regarding Risperdal. [justice.gov/opa/pr/2013/November/13-ag-1170.html, November 4, 2013] [fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373499.htm, November 4, 2013]

Risperdal is approved by the FDA as an atypical antipsychotic drug to treat schizophrenia, bipolar disorder, and irritability in autistic children and adolescents. An investigation by the Los Angeles Daily News showed children in California’s foster care system have been prescribed psychiatric drugs, including Risperdal, Prozac, and Haldol, to control their behavior, although the medications have not been approved by the FDA use by children. The Los Angeles Daily News said it looked at 10 years of data that begins in 2004. The newspaper’s investigation found that nearly 1 out of every 4 adolescents in California’s foster care system is receiving psychiatric drugs, which is three times the rate for all adolescents nationwide. The newspaper reported that of the thousands of foster children prescribed psychotropic drugs in the last 10 years, nearly 60 percent were prescribed an antipsychotic, which are the highest risk psychotropic drugs. The newspaper further reported that the percentage of foster children who were prescribed two or more psychotropic medications increased from 10.1 percent in 2004 to 12.2 percent in 2013.

[dailynews.com/health/20140823/children-in-californias-foster-care-system-are-prescribed-risky-medications, August 23, 2014]

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:

Wright & Schulte LLC

812 East National Road

Vandalia, Ohio 45377

1-800-399-0795

http://www.yourlegalhelp.com

Like us on Facebook

Follow us on Twitter

Join us on Google+







Risperdal Lawsuit Claims Contending Males Taking The Antipsychotic Drug Causes Gynecomastia Move Forward With October Meeting Reports Wright & Schulte LLC


Columbus, OH (PRWEB) October 11, 2014

As Risperdal lawsuit claims continue in the Philadelphia Court of Common Pleas, another monthly meeting has been scheduled for parties to discuss the litigation surrounding antipsychotic drugs and the development of male breasts or gynecomastia. According to court records there are nearly 80 Risperdal lawsuit claims pending in the Philadelphia Court of Common Pleas mass tort program. The court’s calendar shows attorneys for the plaintiffs and defendants are scheduled to meet on October 15, at the Complex Litigation Center in Philadelphia’s City Hall. The Risperdal side-effects complaints were filed on behalf of males who allege that they experienced gynecomastia, which is excessive male breast growth similar to that of a woman after using the antipsychotic drug. The Risperdal side-effect lawsuits purport that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., which manufactures and markets the drug, failed to warn consumers and health care providers about the serious side-effects of taking Risperdal. (In Re: Risperdal Litigation, Case Number 100300296)

Risperdal gynecomastia is a devastating condition that can have far reaching effects on a boy’s social development and quality of life. The attorneys at Wright & Schulte LLC are committed to ensuring that the victims of Risperdal gynecomastia obtain the justice they deserve. To learn more, please contact Wright & Schulte LLC for a free Risperdal lawsuit consultation to ensure you are treated fairly and receive all of the compensation the law allows. Call 1-800-399-0795 or visit http://www.yourlegalhelp.com for more information.

In June, plaintiffs’ attorneys asked Philadelphia Court of Common Pleas Judge Arnold New, who is presiding over the Risperdal litigation, to reconsider his decision of preventing plaintiffs from asking for punitive damages against Janssen Pharmaceuticals, Inc. Judge New issued an order on July 18 reaffirming his earlier decision to deny punitive damages to plaintiffs but they can still ask for compensatory damages. The issue of punitive damages arose as a result of Janssen asking Judge New to allow the New Jersey Product Liability Act to apply in the Risperdal litigation because the company is headquartered in New Jersey. The New Jersey Product Liability Act does not allow punitive damages to be awarded against manufacturers of prescription drugs or medical devices if they have received pre-market approval by the U.S. Food & Drug Administration (FDA). Plaintiffs’ attorneys contend that the defendants marketed Risperdal for uses that were not approved by the FDA and therefore, punitive damages should be allowed. Judge New initially granted Janssen’s motion in an order issued May 2, 2014. (In Re: Risperdal Litigation, Case Number 100300296)

Janssen Pharmaceuticals, Inc., was the subject of a criminal investigation by the U.S. Department of Justice (DOJ) for marketing Risperdal for uses that were not approved by the FDA. According to the DOJ, Janssen did not have FDA approval when the company marketed the antipsychotic medication for use in children and adolescents with behavior challenges and the company did not disclose the health risks associated with use of the drug. In November 2013, the DOJ announced that Janssen was charged with a criminal count of misbranding Risperdal and Janssen pleaded guilty to the charge. The company also agreed to pay a $ 400 million criminal fine. The DOJ said Risperdal was not approved for use in children for any purpose until late 2006. Janssen was also under criminal investigation for marketing Risperdal for unapproved use in elderly dementia patients. The DOJ charged Janssen in this case with introducing a misbranded drug into interstate commerce. The company also paid $ 1.25 billion to settle a separate civil case regarding Risperdal. [justice.gov/opa/pr/2013/November/13-ag-1170.html, November 4, 2013] [fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373499.htm, November 4, 2013]

Risperdal is approved by the FDA as an atypical antipsychotic drug to treat schizophrenia, bipolar disorder, and irritability in autistic children and adolescents. An investigation by the Los Angeles Daily News showed children in California’s foster care system have been prescribed psychiatric drugs, including Risperdal, Prozac, and Haldol, to control their behavior, although the medications have not been approved by the FDA use by children. The Los Angeles Daily News said it looked at 10 years of data that begins in 2004. The newspaper’s investigation found that nearly 1 out of every 4 adolescents in California’s foster care system is receiving psychiatric drugs, which is three times the rate for all adolescents nationwide. The newspaper reported that of the thousands of foster children prescribed psychotropic drugs in the last 10 years, nearly 60 percent were prescribed an antipsychotic, which are the highest risk psychotropic drugs. The newspaper further reported that the percentage of foster children who were prescribed two or more psychotropic medications increased from 10.1 percent in 2004 to 12.2 percent in 2013.

[dailynews.com/health/20140823/children-in-californias-foster-care-system-are-prescribed-risky-medications, August 23, 2014]

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:

Wright & Schulte LLC

812 East National Road

Vandalia, Ohio 45377

1-800-399-0795

http://www.yourlegalhelp.com

Like us on Facebook

Follow us on Twitter

Join us on Google+







CDC Vital Signs Reports: Opioid Painkiller Prescribing Varies Widely Among States


Atlanta, GA (PRWEB) July 02, 2014

Health care providers wrote 259 million prescriptions for opioid painkillers in 2012 – many more in some states than in others – according to a Vital Signs report released today by the Centers for Disease Control and Prevention that highlights the danger of overdose. The report also has an example of a state that reversed its overdose trend.

Health care providers in the highest prescribing state, Alabama, wrote almost three times as many of these prescriptions per person as those in the lowest prescribing state, Hawaii. Most of the highest prescribing states were in the South. Previous research has shown that regional variation in use of prescriptions cannot be explained by the underlying health status of the population.

The Vital Signs report also contains a study highlighting the success of Florida in reversing prescription drug overdose trends. Results showed that after statewide legislative and enforcement actions in 2010 and 2011, the death rate from prescription drug overdose decreased 23 percent between 2010 and 2012. Florida officials had taken these actions in response to a 28 percent increase in the drug overdose death rate over the preceding years (2006-2010).

Declines in death rates in Florida for specific prescription painkillers (oxycodone, methadone, and hydrocodone) and sedatives paralleled declines in prescribing rates for those drugs. This report was based on Florida Medical Examiners Commission data from 2006 to 2012 and IMS Health National Prescription Audit data from 2008 to 2012.

“Prescription drug overdose is epidemic in the United States. All too often, and in far too many communities, the treatment is becoming the problem,” said CDC Director Tom Frieden, M.D., M.P.H. “Overdose rates are higher where these drugs are prescribed more frequently. States and practices where prescribing rates are highest need to take a particularly hard look at ways to reduce the inappropriate prescription of these dangerous drugs.”

For this Vital Signs report, CDC analyzed 2012 prescribing data collected from retail pharmacies in the United States by a commercial vendor. CDC calculated prescribing rates by state for various types of opioid painkillers.

Key findings include:


Southern states – Alabama, Tennessee, and West Virginia in particular – had the most painkiller prescriptions per person.

The Northeast, especially Maine and New Hampshire, had the most prescriptions per person for long-acting/extended-release painkillers and for high-dose painkillers.

State variation was the greatest for oxymorphone (a specific type of painkiller), among all prescription painkillers. Nearly 22 times as many prescriptions were written for oxymorphone in Tennessee as were written in Minnesota.

“We know we can do better. State variation in prescribing shows us that the overprescribing of opioids can be reduced safely and feasibly,” said Daniel M. Sosin, M.D., M.P.H., F.A.C.P., acting director of CDC’s National Center for Injury Prevention and Control. “Improving how opioids are prescribed will help us prevent the 46 prescription painkiller overdose deaths that occur each day in the United States.”

Previous research has shown that state variation does not necessarily translate to better health outcomes or patient satisfaction. In fact, high rates of use might produce worse outcomes.

Steps that states can take to address the overprescribing of painkillers include:

Considering ways to increase use of prescription drug monitoring programs, which are state-run databases that track prescriptions for painkillers and can help find problems in overprescribing. Impact of these programs is greater when they make data available in real time, are universal (used by all prescribers for all prescriptions for all controlled substances), and are actively managed (for example, send alerts to prescribers when problems are identified).

Considering policy options, including laws and regulation, relating to pain clinics to reduce prescribing practices that are risky to patients.

Evaluating their own data and programs and considering ways to assess their Medicaid, workers’ compensation programs, and other state-run health plans to detect and address inappropriate prescribing of painkillers.

Identifying opportunities to increase access to substance abuse treatment and considering expanding first responder access to naloxone, a drug used when people overdose.

CDC’s Injury Center works to protect the safety of everyone, every day. For more information about prescription drug overdoses, please visit http://www.cdc.gov/homeandrecreationalsafety/overdose.

Vital Signs is a CDC report that appears on the first Tuesday of the month as part of the CDC journal Morbidity and Mortality Weekly Report, or MMWR. The report provides the latest data and information on key health indicators. These are cancer prevention, obesity, tobacco use, motor vehicle passenger safety, prescription drug overdose, HIV/AIDS, alcohol use, health care–associated infections, cardiovascular health, teen pregnancy, food safety and viral hepatitis.

###







CDC Vital Signs Reports: Opioid Painkiller Prescribing Varies Widely Among States


Atlanta, GA (PRWEB) July 02, 2014

Health care providers wrote 259 million prescriptions for opioid painkillers in 2012 – many more in some states than in others – according to a Vital Signs report released today by the Centers for Disease Control and Prevention that highlights the danger of overdose. The report also has an example of a state that reversed its overdose trend.

Health care providers in the highest prescribing state, Alabama, wrote almost three times as many of these prescriptions per person as those in the lowest prescribing state, Hawaii. Most of the highest prescribing states were in the South. Previous research has shown that regional variation in use of prescriptions cannot be explained by the underlying health status of the population.

The Vital Signs report also contains a study highlighting the success of Florida in reversing prescription drug overdose trends. Results showed that after statewide legislative and enforcement actions in 2010 and 2011, the death rate from prescription drug overdose decreased 23 percent between 2010 and 2012. Florida officials had taken these actions in response to a 28 percent increase in the drug overdose death rate over the preceding years (2006-2010).

Declines in death rates in Florida for specific prescription painkillers (oxycodone, methadone, and hydrocodone) and sedatives paralleled declines in prescribing rates for those drugs. This report was based on Florida Medical Examiners Commission data from 2006 to 2012 and IMS Health National Prescription Audit data from 2008 to 2012.

“Prescription drug overdose is epidemic in the United States. All too often, and in far too many communities, the treatment is becoming the problem,” said CDC Director Tom Frieden, M.D., M.P.H. “Overdose rates are higher where these drugs are prescribed more frequently. States and practices where prescribing rates are highest need to take a particularly hard look at ways to reduce the inappropriate prescription of these dangerous drugs.”

For this Vital Signs report, CDC analyzed 2012 prescribing data collected from retail pharmacies in the United States by a commercial vendor. CDC calculated prescribing rates by state for various types of opioid painkillers.

Key findings include:


Southern states – Alabama, Tennessee, and West Virginia in particular – had the most painkiller prescriptions per person.

The Northeast, especially Maine and New Hampshire, had the most prescriptions per person for long-acting/extended-release painkillers and for high-dose painkillers.

State variation was the greatest for oxymorphone (a specific type of painkiller), among all prescription painkillers. Nearly 22 times as many prescriptions were written for oxymorphone in Tennessee as were written in Minnesota.

“We know we can do better. State variation in prescribing shows us that the overprescribing of opioids can be reduced safely and feasibly,” said Daniel M. Sosin, M.D., M.P.H., F.A.C.P., acting director of CDC’s National Center for Injury Prevention and Control. “Improving how opioids are prescribed will help us prevent the 46 prescription painkiller overdose deaths that occur each day in the United States.”

Previous research has shown that state variation does not necessarily translate to better health outcomes or patient satisfaction. In fact, high rates of use might produce worse outcomes.

Steps that states can take to address the overprescribing of painkillers include:

Considering ways to increase use of prescription drug monitoring programs, which are state-run databases that track prescriptions for painkillers and can help find problems in overprescribing. Impact of these programs is greater when they make data available in real time, are universal (used by all prescribers for all prescriptions for all controlled substances), and are actively managed (for example, send alerts to prescribers when problems are identified).

Considering policy options, including laws and regulation, relating to pain clinics to reduce prescribing practices that are risky to patients.

Evaluating their own data and programs and considering ways to assess their Medicaid, workers’ compensation programs, and other state-run health plans to detect and address inappropriate prescribing of painkillers.

Identifying opportunities to increase access to substance abuse treatment and considering expanding first responder access to naloxone, a drug used when people overdose.

CDC’s Injury Center works to protect the safety of everyone, every day. For more information about prescription drug overdoses, please visit http://www.cdc.gov/homeandrecreationalsafety/overdose.

Vital Signs is a CDC report that appears on the first Tuesday of the month as part of the CDC journal Morbidity and Mortality Weekly Report, or MMWR. The report provides the latest data and information on key health indicators. These are cancer prevention, obesity, tobacco use, motor vehicle passenger safety, prescription drug overdose, HIV/AIDS, alcohol use, health care–associated infections, cardiovascular health, teen pregnancy, food safety and viral hepatitis.

###







CDC Vital Signs Reports: Opioid Painkiller Prescribing Varies Widely Among States


Atlanta, GA (PRWEB) July 02, 2014

Health care providers wrote 259 million prescriptions for opioid painkillers in 2012 – many more in some states than in others – according to a Vital Signs report released today by the Centers for Disease Control and Prevention that highlights the danger of overdose. The report also has an example of a state that reversed its overdose trend.

Health care providers in the highest prescribing state, Alabama, wrote almost three times as many of these prescriptions per person as those in the lowest prescribing state, Hawaii. Most of the highest prescribing states were in the South. Previous research has shown that regional variation in use of prescriptions cannot be explained by the underlying health status of the population.

The Vital Signs report also contains a study highlighting the success of Florida in reversing prescription drug overdose trends. Results showed that after statewide legislative and enforcement actions in 2010 and 2011, the death rate from prescription drug overdose decreased 23 percent between 2010 and 2012. Florida officials had taken these actions in response to a 28 percent increase in the drug overdose death rate over the preceding years (2006-2010).

Declines in death rates in Florida for specific prescription painkillers (oxycodone, methadone, and hydrocodone) and sedatives paralleled declines in prescribing rates for those drugs. This report was based on Florida Medical Examiners Commission data from 2006 to 2012 and IMS Health National Prescription Audit data from 2008 to 2012.

“Prescription drug overdose is epidemic in the United States. All too often, and in far too many communities, the treatment is becoming the problem,” said CDC Director Tom Frieden, M.D., M.P.H. “Overdose rates are higher where these drugs are prescribed more frequently. States and practices where prescribing rates are highest need to take a particularly hard look at ways to reduce the inappropriate prescription of these dangerous drugs.”

For this Vital Signs report, CDC analyzed 2012 prescribing data collected from retail pharmacies in the United States by a commercial vendor. CDC calculated prescribing rates by state for various types of opioid painkillers.

Key findings include:


Southern states – Alabama, Tennessee, and West Virginia in particular – had the most painkiller prescriptions per person.

The Northeast, especially Maine and New Hampshire, had the most prescriptions per person for long-acting/extended-release painkillers and for high-dose painkillers.

State variation was the greatest for oxymorphone (a specific type of painkiller), among all prescription painkillers. Nearly 22 times as many prescriptions were written for oxymorphone in Tennessee as were written in Minnesota.

“We know we can do better. State variation in prescribing shows us that the overprescribing of opioids can be reduced safely and feasibly,” said Daniel M. Sosin, M.D., M.P.H., F.A.C.P., acting director of CDC’s National Center for Injury Prevention and Control. “Improving how opioids are prescribed will help us prevent the 46 prescription painkiller overdose deaths that occur each day in the United States.”

Previous research has shown that state variation does not necessarily translate to better health outcomes or patient satisfaction. In fact, high rates of use might produce worse outcomes.

Steps that states can take to address the overprescribing of painkillers include:

Considering ways to increase use of prescription drug monitoring programs, which are state-run databases that track prescriptions for painkillers and can help find problems in overprescribing. Impact of these programs is greater when they make data available in real time, are universal (used by all prescribers for all prescriptions for all controlled substances), and are actively managed (for example, send alerts to prescribers when problems are identified).

Considering policy options, including laws and regulation, relating to pain clinics to reduce prescribing practices that are risky to patients.

Evaluating their own data and programs and considering ways to assess their Medicaid, workers’ compensation programs, and other state-run health plans to detect and address inappropriate prescribing of painkillers.

Identifying opportunities to increase access to substance abuse treatment and considering expanding first responder access to naloxone, a drug used when people overdose.

CDC’s Injury Center works to protect the safety of everyone, every day. For more information about prescription drug overdoses, please visit http://www.cdc.gov/homeandrecreationalsafety/overdose.

Vital Signs is a CDC report that appears on the first Tuesday of the month as part of the CDC journal Morbidity and Mortality Weekly Report, or MMWR. The report provides the latest data and information on key health indicators. These are cancer prevention, obesity, tobacco use, motor vehicle passenger safety, prescription drug overdose, HIV/AIDS, alcohol use, health care–associated infections, cardiovascular health, teen pregnancy, food safety and viral hepatitis.

###







Risperdal Lawsuit Claims Contending Males Taking The Antipsychotic Drug Causes Gynecomastia Move Forward With October Meeting Reports Wright & Schulte LLC


Columbus, OH (PRWEB) October 11, 2014

As Risperdal lawsuit claims continue in the Philadelphia Court of Common Pleas, another monthly meeting has been scheduled for parties to discuss the litigation surrounding antipsychotic drugs and the development of male breasts or gynecomastia. According to court records there are nearly 80 Risperdal lawsuit claims pending in the Philadelphia Court of Common Pleas mass tort program. The court’s calendar shows attorneys for the plaintiffs and defendants are scheduled to meet on October 15, at the Complex Litigation Center in Philadelphia’s City Hall. The Risperdal side-effects complaints were filed on behalf of males who allege that they experienced gynecomastia, which is excessive male breast growth similar to that of a woman after using the antipsychotic drug. The Risperdal side-effect lawsuits purport that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., which manufactures and markets the drug, failed to warn consumers and health care providers about the serious side-effects of taking Risperdal. (In Re: Risperdal Litigation, Case Number 100300296)

Risperdal gynecomastia is a devastating condition that can have far reaching effects on a boy’s social development and quality of life. The attorneys at Wright & Schulte LLC are committed to ensuring that the victims of Risperdal gynecomastia obtain the justice they deserve. To learn more, please contact Wright & Schulte LLC for a free Risperdal lawsuit consultation to ensure you are treated fairly and receive all of the compensation the law allows. Call 1-800-399-0795 or visit http://www.yourlegalhelp.com for more information.

In June, plaintiffs’ attorneys asked Philadelphia Court of Common Pleas Judge Arnold New, who is presiding over the Risperdal litigation, to reconsider his decision of preventing plaintiffs from asking for punitive damages against Janssen Pharmaceuticals, Inc. Judge New issued an order on July 18 reaffirming his earlier decision to deny punitive damages to plaintiffs but they can still ask for compensatory damages. The issue of punitive damages arose as a result of Janssen asking Judge New to allow the New Jersey Product Liability Act to apply in the Risperdal litigation because the company is headquartered in New Jersey. The New Jersey Product Liability Act does not allow punitive damages to be awarded against manufacturers of prescription drugs or medical devices if they have received pre-market approval by the U.S. Food & Drug Administration (FDA). Plaintiffs’ attorneys contend that the defendants marketed Risperdal for uses that were not approved by the FDA and therefore, punitive damages should be allowed. Judge New initially granted Janssen’s motion in an order issued May 2, 2014. (In Re: Risperdal Litigation, Case Number 100300296)

Janssen Pharmaceuticals, Inc., was the subject of a criminal investigation by the U.S. Department of Justice (DOJ) for marketing Risperdal for uses that were not approved by the FDA. According to the DOJ, Janssen did not have FDA approval when the company marketed the antipsychotic medication for use in children and adolescents with behavior challenges and the company did not disclose the health risks associated with use of the drug. In November 2013, the DOJ announced that Janssen was charged with a criminal count of misbranding Risperdal and Janssen pleaded guilty to the charge. The company also agreed to pay a $ 400 million criminal fine. The DOJ said Risperdal was not approved for use in children for any purpose until late 2006. Janssen was also under criminal investigation for marketing Risperdal for unapproved use in elderly dementia patients. The DOJ charged Janssen in this case with introducing a misbranded drug into interstate commerce. The company also paid $ 1.25 billion to settle a separate civil case regarding Risperdal. [justice.gov/opa/pr/2013/November/13-ag-1170.html, November 4, 2013] [fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373499.htm, November 4, 2013]

Risperdal is approved by the FDA as an atypical antipsychotic drug to treat schizophrenia, bipolar disorder, and irritability in autistic children and adolescents. An investigation by the Los Angeles Daily News showed children in California’s foster care system have been prescribed psychiatric drugs, including Risperdal, Prozac, and Haldol, to control their behavior, although the medications have not been approved by the FDA use by children. The Los Angeles Daily News said it looked at 10 years of data that begins in 2004. The newspaper’s investigation found that nearly 1 out of every 4 adolescents in California’s foster care system is receiving psychiatric drugs, which is three times the rate for all adolescents nationwide. The newspaper reported that of the thousands of foster children prescribed psychotropic drugs in the last 10 years, nearly 60 percent were prescribed an antipsychotic, which are the highest risk psychotropic drugs. The newspaper further reported that the percentage of foster children who were prescribed two or more psychotropic medications increased from 10.1 percent in 2004 to 12.2 percent in 2013.

[dailynews.com/health/20140823/children-in-californias-foster-care-system-are-prescribed-risky-medications, August 23, 2014]

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:

Wright & Schulte LLC

812 East National Road

Vandalia, Ohio 45377

1-800-399-0795

http://www.yourlegalhelp.com

Like us on Facebook

Follow us on Twitter

Join us on Google+







Risperdal Lawsuit Claims Contending Males Taking The Antipsychotic Drug Causes Gynecomastia Move Forward With October Meeting Reports Wright & Schulte LLC


Columbus, OH (PRWEB) October 11, 2014

As Risperdal lawsuit claims continue in the Philadelphia Court of Common Pleas, another monthly meeting has been scheduled for parties to discuss the litigation surrounding antipsychotic drugs and the development of male breasts or gynecomastia. According to court records there are nearly 80 Risperdal lawsuit claims pending in the Philadelphia Court of Common Pleas mass tort program. The court’s calendar shows attorneys for the plaintiffs and defendants are scheduled to meet on October 15, at the Complex Litigation Center in Philadelphia’s City Hall. The Risperdal side-effects complaints were filed on behalf of males who allege that they experienced gynecomastia, which is excessive male breast growth similar to that of a woman after using the antipsychotic drug. The Risperdal side-effect lawsuits purport that Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc., which manufactures and markets the drug, failed to warn consumers and health care providers about the serious side-effects of taking Risperdal. (In Re: Risperdal Litigation, Case Number 100300296)

Risperdal gynecomastia is a devastating condition that can have far reaching effects on a boy’s social development and quality of life. The attorneys at Wright & Schulte LLC are committed to ensuring that the victims of Risperdal gynecomastia obtain the justice they deserve. To learn more, please contact Wright & Schulte LLC for a free Risperdal lawsuit consultation to ensure you are treated fairly and receive all of the compensation the law allows. Call 1-800-399-0795 or visit http://www.yourlegalhelp.com for more information.

In June, plaintiffs’ attorneys asked Philadelphia Court of Common Pleas Judge Arnold New, who is presiding over the Risperdal litigation, to reconsider his decision of preventing plaintiffs from asking for punitive damages against Janssen Pharmaceuticals, Inc. Judge New issued an order on July 18 reaffirming his earlier decision to deny punitive damages to plaintiffs but they can still ask for compensatory damages. The issue of punitive damages arose as a result of Janssen asking Judge New to allow the New Jersey Product Liability Act to apply in the Risperdal litigation because the company is headquartered in New Jersey. The New Jersey Product Liability Act does not allow punitive damages to be awarded against manufacturers of prescription drugs or medical devices if they have received pre-market approval by the U.S. Food & Drug Administration (FDA). Plaintiffs’ attorneys contend that the defendants marketed Risperdal for uses that were not approved by the FDA and therefore, punitive damages should be allowed. Judge New initially granted Janssen’s motion in an order issued May 2, 2014. (In Re: Risperdal Litigation, Case Number 100300296)

Janssen Pharmaceuticals, Inc., was the subject of a criminal investigation by the U.S. Department of Justice (DOJ) for marketing Risperdal for uses that were not approved by the FDA. According to the DOJ, Janssen did not have FDA approval when the company marketed the antipsychotic medication for use in children and adolescents with behavior challenges and the company did not disclose the health risks associated with use of the drug. In November 2013, the DOJ announced that Janssen was charged with a criminal count of misbranding Risperdal and Janssen pleaded guilty to the charge. The company also agreed to pay a $ 400 million criminal fine. The DOJ said Risperdal was not approved for use in children for any purpose until late 2006. Janssen was also under criminal investigation for marketing Risperdal for unapproved use in elderly dementia patients. The DOJ charged Janssen in this case with introducing a misbranded drug into interstate commerce. The company also paid $ 1.25 billion to settle a separate civil case regarding Risperdal. [justice.gov/opa/pr/2013/November/13-ag-1170.html, November 4, 2013] [fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373499.htm, November 4, 2013]

Risperdal is approved by the FDA as an atypical antipsychotic drug to treat schizophrenia, bipolar disorder, and irritability in autistic children and adolescents. An investigation by the Los Angeles Daily News showed children in California’s foster care system have been prescribed psychiatric drugs, including Risperdal, Prozac, and Haldol, to control their behavior, although the medications have not been approved by the FDA use by children. The Los Angeles Daily News said it looked at 10 years of data that begins in 2004. The newspaper’s investigation found that nearly 1 out of every 4 adolescents in California’s foster care system is receiving psychiatric drugs, which is three times the rate for all adolescents nationwide. The newspaper reported that of the thousands of foster children prescribed psychotropic drugs in the last 10 years, nearly 60 percent were prescribed an antipsychotic, which are the highest risk psychotropic drugs. The newspaper further reported that the percentage of foster children who were prescribed two or more psychotropic medications increased from 10.1 percent in 2004 to 12.2 percent in 2013.

[dailynews.com/health/20140823/children-in-californias-foster-care-system-are-prescribed-risky-medications, August 23, 2014]

About Wright & Schulte LLC

Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Risperdal lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:

Wright & Schulte LLC

812 East National Road

Vandalia, Ohio 45377

1-800-399-0795

http://www.yourlegalhelp.com

Like us on Facebook

Follow us on Twitter

Join us on Google+